Keros Therapeutics (KROS) Operating Leases (2019 - 2025)

Keros Therapeutics has reported Operating Leases for 7 years, with the latest figure at $16.9 million in Q4 2025.

• For the quarter ending Q4 2025, Operating Leases changed 0.0% year-over-year to $16.9 million; the trailing twelve-month figure through Dec 2025 stood at $16.9 million (changed 0.0% YoY), and the FY2025 full-year result was $16.9 million, changed 0.0% from the prior year.
• Operating Leases for Q4 2025 stood at $16.9 million, up from $15.1 million in the prior quarter.
• The five-year high for Operating Leases was $17.4 million in Q3 2024, with the low at $231000.0 in Q4 2021.
• Historically, Operating Leases has averaged $10.7 million across 5 years, with a median of $13.4 million in 2023.
• Annual changes were most pronounced in 2021 — Operating Leases plunged 65.03% — and 2022, when it surged 5484.42%.
• Keros Therapeutics' Operating Leases stood at $231000.0 in 2021, then surged by 5484.42% to $12.9 million in 2022, then grew by 4.18% to $13.4 million in 2023, then advanced by 25.63% to $16.9 million in 2024, then changed by 0.0% to $16.9 million in 2025.
• The last three Operating Leases figures came in at $16.9 million (Q4 2025), $15.1 million (Q3 2025), and $15.7 million (Q2 2025), per Business Quant data.